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SUMMARY
Aims: Patients with Fabry disease (FD) characteristically develop peripheral neuropathy at
an early age, with pain being a crucial symptom of underlying pathology. However, the
diagnosis of pain is challenging due to the heterogeneous and nonspecific symptoms. Practi-
cal guidance on the diagnosis and management of pain in FD is needed.Methods: In 2014,
experts met to discuss recent advances on this topic and update clinical guidance. Results:
Emerging disease-specific tools, including FabryScan, Fabry-specific Pediatric Health and
Pain Questionnaire, and W€urzburg Fabry Pain Questionnaire, and more general tools like
the Total Symptom Score can aid diagnosis, characterization, and monitoring of pain in
patients with FD. These tools can be complemented by more objective and quantifiable sen-
sory testing. In male and female patients of any age, pain related to FD can be an early indi-
cation to start disease-specific enzyme replacement therapy before potentially irreversible
organ damage to the kidneys, heart, or brain occurs. Conclusion: To improve treatment
outcomes, pain should be diagnosed early in unrecognized or newly identified FD patients.
Treatment should include: (a) enzyme replacement therapy controlling the progression of
underlying pathology; (b) adjunctive, symptomatic pain management with analgesics for
chronic neuropathic and acute nociceptive, and inflammatory or mixed pain; and (c) life-
style modifications.
Introduction
Fabry disease (FD) is an X-linked inherited lysosomal storage dis-
order, manifesting as a multisystemic disease. Due to mutations in
the GLA gene encoding the enzyme a-galactosidase A (abbreviated
as a-Gal), accumulation of glycolipids, mainly globotriaosylce-
ramide (GL-3), occurs in a wide range of cell types including vas-
cular endothelial and smooth muscle cells [1]. Elevated plasma
levels of the deacylated metabolite of GL-3, lyso-GL-3, is also a
hallmark of FD [2]. Glycolipid accumulation is often evident from
a very early age, even in utero and in the umbilical cord [3], and
may trigger a range of pathological processes that can ultimately
lead to potentially fatal complications in the kidneys, heart, and
cerebrovascular system [1]. FD covers a wide spectrum of clinical
presentations [4], including the classic severe phenotype, late-
onset variant phenotypes, and the oligosymptomatic presenta-
tions that can be observed in female patients [1,5]. Since 2001,
enzyme replacement therapy (ERT) with recombinant agalsidase
has been available for the treatment of FD.
Pain, one of the earliest clinical symptoms of FD reported by
children and young adults [6–9], has significant physical and
social impacts on patient’s quality of life [10,11]. Although
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long-term improvement has been observed after ERT initiation,
particularly in male patients, life-impacting pain may still be pre-
sent and require the use of adjunctive medications [11].
As pain may be an indicator of underlying FD pathology [12],
any type of pain related to FD is an important symptom that can
indicate the need to start ERT, regardless of patient age or gender
[13].
Materials and Methods
This article aims to provide practical diagnostic and management
guidelines regarding pain in FD. These recommendations are
based on an FD Expert Panel that convened in Rome, Italy, in
March 2014 and on subsequent discussions.
Results
Characteristics and Clinical Course of Pain in
Classic Fabry Disease
Pain is a commonly reported early symptom in FD, affecting 60–
70% of male and 40–60% of female patients [7,14–16]. A recent
systematic literature review showed that the most frequently
reported symptom in patients aged <5 years was pain and/or
dysesthesias, which develop in children aged 2–4 years [9]. The
fingertips, palms, toes, and soles of the feet are the sites commonly
affected by pain in FD (Figure 1) [16]. However, pain may develop
in any body region, such as the joints, teeth, or shoulders [16],
some of which, like joint pain, can easily be overlooked or misdi-
agnosed. A recent survey helped characterize several types of pain
in FD [16]. Typically, pain in FD manifests as episodes of burning,
stabbing, tingling, or shooting pain (previously misleadingly
referred to as “acroparesthesias”) that begin in the distal extremi-
ties and radiate proximally [10,16]. Patients also commonly expe-
rience attacks of excruciating, incapacitating pain that may spread
over the entire body, referred to as “pain crises”, as well as evoked
pain comprising allodynia and hyperalgesia [16]. The most impor-
tant triggers of pain in FD are physical exercise, thermal stimuli,
and fever [7,12,16], but some patients may also develop perma-
nent pain of mostly mild-to-moderate intensity that manifests
mainly at the hands and feet and persists even in the absence of
identifiable triggers [16]. Although pain manifests in early child-
hood, it seems that the timing of pain onset varies according to
gender, starting earlier in males than in females [7,9,12].
Interestingly, several patients with FD report a reduction in pain
as they reach adulthood [16], but they can develop symptoms of
large nerve fiber impairment, which mostly manifest as uremic
polyneuropathy [17]. Entrapment syndromes, such as carpal tun-
nel syndrome, have been reported in up to a quarter of patients
with FD [18,19]. Another important issue is the high prevalence
of depression in patients with FD that may be associated with pain
[20,21]. It is of note that pain in FD may also manifest as gastroin-
testinal pain and other gastrointestinal symptoms [22]. All of these
indicate the variety of pain manifestations associated with FD.
Figure 1 Potential locations of pain
manifestations in patients with Fabry disease.
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Pain Mechanisms in Fabry Disease
The different types of pain reported by patients with FD may be
sustained by diverse mechanisms, and their characterization is
highly important for appropriate, individually targeted symp-
tomatic pain treatment. Since describing all potential pathophysi-
ological mechanisms of pain in patients with FD is beyond the
scope of this review, focus is on the most relevant mechanisms
with supporting evidence.
Pain in FD is assumed to be predominantly neuropathic, because
of its frequently reported neuropathic characteristics and reports of
GL-3 deposits in the dorsal root ganglion neurons of patients with
FD (Figure 2) which may cause the frequently experienced
“shooting pains” [23,24]. Pain in FD is known as small fiber neu-
ropathy as patients have a predominantly length-dependent
reduction in the density of small, thinly myelinated Ad nerve
fibers (mediating pricking pain, cold perception) and unmyelinated
C nerve fibers (mediating “slow” pain, warmth, and heat percep-
tion) [25,26]. The functional impairment of small fiber conduction
is particularly associated with increased heat and cold pain percep-
tion, suggesting damage to Ad and C nerve fibers [25,27]. Pain in
FD also presents with components that are typical of nociceptive
or inflammatory pain, as evidenced by the efficacy of nonsteroidal
anti-inflammatory drugs (NSAIDs) in many patients [16]. Recent
experimental studies have suggested that some of the spontaneous
types of pain in patients with FD may be explained by hyperex-
citability of peripheral nociceptive neurons mediated by upregula-
tion of sodium ion channels (Nav1.8) [28], transient receptor
potential cation channel subfamily V member 1 (TRPV1) [28], or a
lyso-GL-3-dependent increase in calcium (Ca2+) influx [29].
Other mechanisms that may be responsible for pain in patients
with FD include spontaneous ectopic firing, altered pain modula-
tion, or central nervous system sensitization [17]. Repeated bouts
of peripheral neuropathic pain in epigenetically vulnerable indi-
viduals (i.e., those with genetic risk and multiple stressors) may
sensitize the central neural pain matrix, such that all pain in the
body becomes amplified. As there is overlap between central neu-
ral pain perception and neural connectivity related to memory,
fatigue, sleep, and mood, it may be that central sensitization of
pain may also contribute to fatigue, sleep disorders, and other
problems in vulnerable patients with FD, as suggested for
fibromyalgia [30].
Diagnosis of Pain in Fabry Disease
Differential Diagnosis
Fabry patients who present with chronic pain may receive incor-
rect diagnoses, due to the unspecific nature of pain in FD [1].
These diagnoses represent primary and secondary causes of small
fiber neuropathy [17], and can include diabetic polyneuropathy,
postherpetic neuralgia, autoimmune neuropathy, fibromyalgia
syndrome, rheumatism, amyloidosis, growing pains (essentially in
preschool pediatric patients), radiculopathy, trauma, postopera-
tive pain, complex regional pain syndrome, erythromelalgia,
paroxysmal extreme pain disorder, idiopathic small fiber neuropa-
thy, and celiac disease. Consequently, there may be more than a
10-year delay in the diagnosis of FD [8].
Diagnostic Methods
Diagnosing “undiagnosed” patients
Diagnosing FD-associated neuropathy requires careful assessment
starting with, and based upon, a detailed medical history, a thor-
ough physical examination, and comprehensive pain assessment.
A detailed medical history is of paramount importance and should
include a family history, the temporal course of pain, details of
any autonomic symptoms, and any previous or current medica-
tion. Typical questions should include the following:
• Does the patient have pain crises?
• Although not common to all patients, pain crises are a diag-
nostic red flag that should raise suspicion of FD or other
causes of small fiber neuropathy. As mentioned earlier, pain
crises are characterized by excruciating, unbearable pain,
often beginning in the distal part of the extremities and radi-
ating proximally and to the rest of the body. They can last
hours or days, and persist despite the elimination of the trig-
ger (e.g., fever). Treatment of pain crises is very difficult.
• Does the patient have, or recall having, any “burning” pain
in hands or feet?
• Is there any deterioration or spreading of the pain distribution
with heat or cold exposure, physical effort (such as sports),
stress, or fever?
• Has the pain ever prevented, or does the pain currently pre-
vent, the patient from participating in sports?
• Does the patient sweat less than others or not at all during
physical effort, or in a warm/hot environment (e.g., on a hot
summer day)?
• Are there any family members who have had or currently
have similar complaints?
In addition to the most common differential diagnoses described
above, the patient’s medical history may suggest other possible
causes of pain that should be considered.
If FD is suspected, the diagnosis must be confirmed by a-Gal
enzyme activity andGLAmutation analysis [31]. This is particularly
important in women, who often have normal levels of a-Gal due to
the heterozygous nature of their condition [5]. Standardized and
validated pain questionnaires, complemented with sensory testing,
Figure 2 Dorsal root ganglion cells from a Fabry patient. The ganglion
cells are swollen because of glycolipid accumulation. Image from Burlina
et al. [17]. Photo courtesy of E. Kaye.
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should then be used to characterize and evaluate the pain. This
allows the longitudinal follow-up of pain severity and its impact on
daily life, and provides the opportunity to assess the effect of ERT
and supportive pain-management strategies.
Pain assessment tools
In recent years, FD-specific pain questionnaires have been pub-
lished for children and adults (Table 1). Pain during childhood
can now be captured as part of the Fabry-specific Pediatric Health
and Pain Questionnaire [32] as well as with the well-established
general pain scales such as the Brief Pain Inventory (BPI), Short-
Form (SF) McGill Pain Questionnaire, or as part of the SF-36
health-related quality of life assessment. The first face-to-face
questionnaire for adult patients with FD was published recently
and a self-administered version is now available [33,34]. The
W€urzburg Fabry Pain Questionnaire comprises 22 open questions
assessing the four main pain phenotypes in childhood and adoles-
cence, pain history prior to and during ERT, pain characters, pain
triggers, and impairments of daily life due to pain.
In addition to FD-specific pain questionnaires, there are several
other valuable pain assessment tools that can be used to evaluate
different aspects of pain in FD. The most notable are the Neuro-
pathic Pain Symptom Inventory (NPSI) [35], the Neuropathic Pain
Questionnaire (NPQ) [36], the DN4 questionnaire [37], the pain-
DETECT questionnaire [38], the LANSS Pain Scale [39], and the
ID Pain questionnaire [40]. The Total Symptom Score is a more
general tool originally developed to assess neuropathic pain in
patients with diabetes; it can provide a rapid assessment of pain
type, severity, and frequency [27,41].
FabryScan is a 15-item questionnaire with three bedside sensory
function tests that assesses small and large fiber function. It helps
distinguish pain in FD from other forms of chronic neuropathic
pain [42], and identify FD patients with chronic extremity pain.
Sensory testing
In addition to pain questionnaires, tests for thermal and pain per-
ception deficits and touch and vibration perception deficits are
important to determine the extent of peripheral nerve fiber
involvement in patients with FD. Specialized centers are able to
perform distinct tests, such as quantitative sensory testing (QST)
[43] for the functional investigation of small nerve fibers and skin
punch biopsies to quantify intra-epidermal nerve fiber density
(Table 1) [44].
If these tests are unavailable, there is a range of “bedside” sen-
sory tests that can be carried out by general neurologists to charac-
terize pain and sensory deficits in patients with FD (Table 1).
Small nerve fibers (Ad and C) require special attention and need
specific tests to determine their function and morphology. These
include assessment of cold perception (Ad function); warmth, heat
pain, and pain perception (unmyelinated C fibers); and response
to sharp pinprick (Ad function). Thermal perception can be evalu-
ated by: (a) assessing the ability to discriminate the temperature of
glass tubes filled with warm or cold water; (b) devices with sur-
faces such as polyvinyl or metal disks which mediate warm or cold
temperature sensation, respectively, when placed on the patient’s
hand or foot [45]; or (c) using the so-called “ice-bucket” test. The
ice-bucket thermal challenge test can be particularly useful in cen-
ters with limited resources. It involves the patient plunging a leg
or arm into iced water (up to mid-thigh or elbow) for up to 30 sec-
onds. Normal subjects would tolerate the cold challenge, but a
patient with FD is likely to experience intense burning pain within
15–20 seconds [46].
Large nerve fiber abnormalities (particularly in Ab fibers that
mediate vibration perception and touch) usually present in
more advanced stages of the disease, require evaluation as part
of the neurological examination of patients with FD, and can be
tested with light-touch tests and vibration perception (Ab func-
tion) [47,48]. Light-touch tests assess proximal versus distal sen-
sation loss and can be performed using a cotton swab (skin
brushing). Vibration sensitivity should be evaluated against nor-
mative values for vibratory perception using a 128 Hz-scaled
Rydel-Seiffer vibrating tuning fork [49]. Pain perception can be
tested by evaluating a patient’s pinprick sensation, exerting just
enough pressure with the point of a sharp pin to dent the skin.
If the patient is unable to distinguish between the sharp pin-
prick and blunt pressure, small fiber neuropathy is suggested.
Table 1 Recommended approach to the assessment of the peripheral nervous system in the evaluation of patients with Fabry disease
Neurologist evaluation Specialist assessment
General evaluations and pain Medical history: especially family history W€urzburg Fabry Pain Questionnaire (adults)
Physical examination: including height, weight, heart rate,
standing and supine blood pressure, and skin examination
for angiokeratoma
Total Symptom Score
Pain evaluation: temporal course of pain, localization of pain,
characteristics of pain, and quantification of pain using general
pain assessment scales (e.g., Brief Pain Inventory, Short-Form
McGill Pain Questionnaire, and Fabry-specific [FabryScan])
Fabry-specific Pediatric Health and Pain
Questionnaire (children/adolescents)
Somatosensory evaluation Thermal perception tests (thermal disks; hot-, warm-,
cold-water tubes)
Quantitative sensory testing, nociceptive
evoked potentials, analysis of skin biopsies
(intra-epidermal nerve fiber density)Cold perception tests (ice-bucket test, cold-water tubes)
Pinprick pain perception test
Touch perception (skin-brushing test)
Vibration perception (e.g., 8/8 scaled vibrating 128 Hz Rydel-Seiffer
tuning fork held to medial malleolus as used in FabryScan)
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Carpal tunnel syndrome can be investigated with nerve conduc-
tion studies [19].
Overall, there is no evidence for one test being better than
another. This is partly because some assessment tools, such as the
FabryScan and the W€urzburg Fabry Pain Questionnaire, have
been introduced only quite recently. These tools have been used
to show changes in pain perception, and future clinical use of
these tools will provide evidence of their value. Furthermore,
some tests are available only in specific units devoted to the study
of peripheral nerve pathology (e.g., QST, nociceptive evoked
potentials, and skin biopsy). A recommended screening strategy
should include the BPI, FabryScan, ice-bucket test, and all the
somatosensory evaluation tests listed in Table 1. Indeed, these
tests are readily available and are usually performed by the neu-
rologist; however, the specialist assessments may not always be
available. QST and skin biopsies are the most widely used small
nerve fiber assessment tools and are recommended to be per-
formed, if available, together with the assessment of nociceptive
evoked potentials.
Treatment of Pain in Fabry Disease
Pain, an early sign of peripheral nervous system involvement in
FD, indicates nervous system damage [50] and, therefore,
requires effective treatment. Treatment of pain in FD has two
aims, each of which requires a different therapeutic approach:
slowing progression of Fabry pathology and achieving pain con-
trol. ERT has been shown to slow disease progression and reduce
renal or cardiac complications. Pain management may be
achieved through disease-specific treatment with ERT, supportive
symptomatic treatment with analgesic drugs, and strategies to
avoid the abovementioned pain triggers. In addition, nonpharma-
cologic approaches including psychological and physical treat-
ments have been proven effective in the relief of pain and the
treatment of comorbid disorders including anxiety and depression
[51]. Among the psychological treatments, cognitive-behavioral
therapies are most commonly implemented to treat chronic pain
[51].
Enzyme Replacement Therapy
The underlying deficiency in a-Gal can be treated with ERT: either
agalsidase beta 1.0 mg/kg every 2 weeks (Fabrazyme; Sanofi Gen-
zyme) or agalsidase alfa 0.2 mg/kg every 2 weeks (Replagal; Shire
Human Genetic Therapies Inc.). Currently, both ERTs are avail-
able in the European Union and other countries worldwide, but
only agalsidase beta is licensed in the USA. In 2014, a biosimilar
agalsidase beta (Fabagal; ISU Abxis, ISU Global) was approved in
South Korea.
Clinical evidence indicates that early initiation of ERT is associ-
ated with better clinical outcomes [52], reducing or delaying the
development of irreversible damage to the kidneys and heart
[53,54]. Considering that damage to small nerve fibers occurs
early, prompt treatment is important in order to limit damage to
the peripheral nervous system [26]. As noted above, increased
lyso-GL-3 levels are directly associated with pain in FD, hence
timely initiation of ERT at adequate doses is a key component of
pain-reduction strategy [29]. Clinical studies have shown that
ERT may improve overall pain scores and pain intensity in
patients with FD [11,27,55,56]; improvements in pain outcomes
have been sustained during long-term follow-up, allowing many
patients to reduce their use of pain medication [57,58]. Long-term
studies in children have also reported that ERT can reduce Fabry-
associated neuropathic and gastrointestinal pain [59,60]. In
another pediatric study, FD patients with morphological evidence
of early kidney damage also presented with high pain scores at
baseline that improved during treatment with agalsidase beta
[53]. In terms of small nerve fiber sensory function, a study of 22
patients with FD revealed improved thermal perception and vibra-
tion detection thresholds with agalsidase beta [27]. Although ERT
reduces pain outcomes in a variety of Fabry-related pain condi-
tions, pain does not always completely resolve [55–62], explaining
the need for adjunctive medications.
The licensed doses are 1.0 mg/kg every 2 weeks for agalsidase
beta and 0.2 mg/kg every 2 weeks for agalsidase alfa (5-fold dif-
ference). These two ERT agents have not been directly compared
in terms of pain outcomes. Data from the Canadian Fabry Disease
Initiative, in which agalsidase alfa and agalsidase beta were used
head-to-head, have shown no difference in clinical endpoints
between patients treated with one or the other ERT. However,
pain outcome data were not reported; the only data referring to
peripheral nerve involvement present in the analysis were those
related to hearing loss outcome; patients were not randomized for
variables known to affect prognosis, leading to an uneven patient
distribution; and the study was underpowered due to limited
event rates and measures taken to account for temporary world-
wide shortage of agalsidase beta [63]. There is some indirect evi-
dence from dose-switching studies that suggests that ERT dose
may be of relevance for pain outcomes, at least in the short term.
At 1-year follow-up, there was improvement or stabilization of
pain symptoms in patients who continued treatment with agalsi-
dase beta, but an increase in pain when patients receiving agalsi-
dase beta were transferred to treatment with agalsidase alfa [61].
In a different study, patients who switched from agalsidase beta
1.0 mg/kg to a lower dose or to agalsidase alfa 0.2 mg/kg reported
an increase in pain attacks, chronic pain, gastrointestinal pain,
and diarrhea compared with those who continued receiving agal-
sidase beta 1.0 mg/kg after 1 year [62]. At the 2-year follow-up of
the same study, there was no significant difference in the fre-
quency of pain attacks or permanent pain in patients who had
switched or reduced their dose; however, the frequency of gas-
trointestinal pain increased, kidney function deteriorated, and
overall disease severity increased [64]. Considering the potential
link between lyso-GL-3 and pain [29], lowering lyso-GL-3 levels,
using early and adequately dosed ERT, may help decrease pain
severity.
Supportive/Symptomatic Pain Control
Pain management strategy
As a consequence of the heterogeneous nature of pain in FD,
patients require individual pain-management strategies alongside
ERT. Advice on lifestyle modifications, such as the use of air con-
ditioning to avoid overheating, taking off shoes and socks during
pain attacks, rapid treatment of fever or infections, and maintain-
ing good levels of hydration, may help to avoid pain triggers and
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should be included in the patient’s pain-management plan as
appropriate. It is important to consider the underlying mechanism
of pain for the patient’s symptoms and, where possible, use a tar-
geted approach tailored to the type of pain involved. Importantly,
patients should be counseled that it is not always possible to elimi-
nate pain, but rather that the treatment goal should be to make
pain manageable. In this context a pain diary may be useful, par-
ticularly during changes in pain medication, in order to document
pain development as well as the level of pain control achieved.
With good pain management, functional improvement may pre-
cede a decline in pain perception; therefore, changes in function
should also be a guide regarding efficacy of ERT.
To reduce the likelihood of side effects from polypharmacy, the
dosage of each drug prescribed should be titrated to the highest
tolerated dose providing significant pain control (with appropriate
consideration of any possible cardiac and renal contraindications)
before other pain-modulating agents are added. Some patients,
particularly the elderly, can present with other comorbidities such
as osteopenia or osteoporosis [65], which also cause pain, or with
conditions that are contraindications for certain adjunctive anti-
pain medications. For example, tricyclic antidepressants can
increase the risk of cardiac arrhythmia and, therefore, should be
avoided in elderly patients.
Neuropathic pain control agents
A recent survey found that frequently used acute pain medica-
tions among patients with FD include the NSAIDs and non-opioid
analgesics, with few patients using neuropathic pain-control
agents [16]. This could be because there are limited comparative
clinical data regarding the use of neuropathic pain-control
agents in patients with FD as a specific group. Nevertheless, case
reports of small numbers of patients with FD have shown that
pain can be reduced with the administration of carbamazepine,
gabapentin, phenytoin, and intravenous lidocaine [66–69]
(Tables 2 and 3).
Current pain-management strategies are founded on clinical
experience or follow national and international guidelines for the
management of neuropathic pain [51,70,71]. Based on a system-
atic literature review and meta-analysis of pharmacotherapy for
the management of neuropathic pain in adults, tricyclic antide-
pressants, serotonin and norepinephrine reuptake inhibitors (e.g.,
duloxetine, venlafaxine), carbamazepine, gabapentin, and the
gabapentinoid pregabalin should be considered as first-line
options; lidocaine patches, topical capsaicin (8%) patches, and tra-
madol should be considered as second-line options; strong opioids
should be considered as third-line options [70]. Controlled-release
opioids are preferred over short-acting opioids. Cannabinoids are
also now recommended as third-line treatments. Fourth-line
treatments may include methadone (with both N-methyl-D-aspar-
tate and opioid receptor effects), anticonvulsants with lesser evi-
dence of efficacy (e.g., lamotrigine, lacosamide), tapentadol, and
botulinum toxin [72].
Evidence regarding the use of neuropathic pain control agents
specifically in patients with FD has been summarized in Table 2
(chronic pain) [66–68,70,73] and Table 3 (acute pain) [69,73–75].
Lidocaine and capsaicin plasters may be useful to control localized
pain as well as during pain crises. However, the mostly episodic
nature of pain in FD reduces the appropriateness of these drugs.
Furthermore, in FD, the area affected by pain crises is too large for
plasters. Based on our clinical experience, lidocaine or capsaicin
cream may be used as acute-pain prophylaxis before physical
activity. There is some evidence to suggest that phenytoin may be
useful during pain attacks [68]. More recently, intravenous lido-
caine has been used to successfully treat FD pain crises [69]. Opi-
oid agonists may also be effective during pain crises, but should be
Table 2 Recommended analgesic drugs for supportive treatment of chronic neuropathic pain in Fabry disease
Agent Dose
Expert panel
comment Cardiac restrictions Renal restrictions Clinical evidence
Carbamazepine 250–800 mg/day Good clinical
experience
May interfere with
activity of other drugs,
e.g., warfarin
None Filling-Katz et al. [66]
Gabapentin Slowly titrated from
100 mg/day to
max. 2400 mg/day
Good clinical
experience
None Yes (with precaution in cases
of renal insufficiency)
Ries et al. [67]
Phenytoin 300 mg/day Good clinical
experience
None None Lockman et al. [68]
Pregabalin 75–300 mg/day None Yes (with precaution in cases
of renal insufficiency)
Expert panel clinical
experience
Tricyclic antidepressants 12.5–150 mg Avoid due to risk of
arrhythmias
Unknown Expert panel clinical
experience
Serotonin-norepinephrine
reuptake inhibitors
Sommer et al. [73];
Finnerup et al. [70]
Duloxetine 60–120 mg/day None None
Venlafaxine 150–225 mg ER/day QT-interval prolongation Dose adjustment according
to renal function
Relevant studies are listed where available; however, as limited clinical evidence has been published, recommendations are based on the clinical
experience of the authors. Table has been adapted from Sommer et al. [73]. ER, extended release.
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used only when anticonvulsant agents are ineffective in order to
avoid worsening of gut motility problems [76] and reduce the risk
of dependency [17]. Ketamine has been used to effectively treat
pain with a neuropathic component; however, because of its
adverse events and potential addiction risks, its use should be
restricted to therapy-resistant severe neuropathic pain until defi-
nite proof that its benefits outweigh the risks and costs of treat-
ment [77]. Finally, although the potential of alpha-2
adrenoceptor agonists for the management of chronic neuropathic
pain has also been explored, further clinical trials in this area are
probably required [78]. Because of the distinct phenotype and
comorbidities in FD patients and since evidence for the use of
analgesic treatment in FD is scarce, individual recommendations
will be necessary in most cases.
Clinical Monitoring of Pain in Fabry Disease
Due to the progressive nature of FD pathology, regular monitoring
of peripheral nervous system symptoms and autonomic function
is required throughout treatment. For peripheral nervous system
symptoms, a comprehensive neurologic assessment should be
conducted at diagnosis, at ERT initiation (if not at the same time
as diagnosis), and prior to the start of supportive analgesic treat-
ment. Follow-up assessments with the patient’s primary care
physician or neurologist should be carried out regularly to review
doses of analgesics and the level of pain control. Analgesic drugs
only provide symptomatic treatment of pain. Therefore, it is also
important to ensure that the patients, caregivers, and the multidis-
ciplinary physician team appreciate that disease-specific therapy
with ERT is necessary to control the progression of the underlying
FD pathology.
Conclusion
Pain occurs frequently in the majority of male and female patients
with FD. In fact, pain should be considered a very early red flag,
useful to confirm a diagnosis of FD. When treatment is indicated
before renal function decline, ERT may improve small nerve fiber
function and help decrease pain; there is some evidence suggesting
that ERT dose is relevant. Adjunctive pain management, using a
combination of analgesics, is targeted at the underlying painmech-
anisms for chronic neuropathic and acute nociceptive, and inflam-
matory or mixed pain. In conclusion, early initiation of ERT and
good supportive pain management using adjunctive therapies may
improve the patient’s quality of life as well as reduce or delay the
likelihood of life-threatening renal and cardiac complications [52].
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